![Steven Xu Tan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenienza dei contatti di primo grado di Steven Xu Tan
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
China Telecom (Americas) Corp.
![]() China Telecom (Americas) Corp. Specialty TelecommunicationsCommunications China Telecom (Americas) Corp. is a private carrier and leading provider of communications and IT solutions for multinational enterprises and service providers in the Americas. The company is based in Herndon, VA. China Telecom (Americas has offices in multiple locations throughout the Americas and is ultimately controlled by the Government of China. Founded in 2000, the company serves as a bridge to China and provides sales and support personnel across the Americas who are equipped with the necessary market expertise to successfully navigate local regulations, languages, and technical specifications to deploy IT solutions faster.
1
| Subsidiary | Specialty Telecommunications | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Steven Xu Tan tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Celtic Pharma Management LP
![]() Celtic Pharma Management LP Investment ManagersFinance Celtic Pharma Management LP is a private equity firm founded by Stephen Evans Freke and John Mayo in 2004. The firm headquartered in Bermuda. | Investment Managers | Private Equity Investor | |
Auven Therapeutics Management LLLP
![]() Auven Therapeutics Management LLLP Investment ManagersFinance Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP. | Investment Managers | Private Equity Investor | |
Harvard University
![]() Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree | |
INOZYME PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Longitude Capital Management Co LLC
![]() Longitude Capital Management Co LLC Investment ManagersFinance Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor | |
DA Advisors LLC | Private Equity Investor | ||
Harvard Business School | College/University | Masters Business Admin | |
LEXEO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
CrownWheel Partners LLC
![]() CrownWheel Partners LLC Financial ConglomeratesFinance CrownWheel Partners LLC engages in the provision of structure financing solutions with healthcare companies, academic institutions, and inventors. It focuses on the monetization of royalty streams, revenue participation, and purchase of structured debt and equity. The company was founded by Sandip K. Agarwala in 2013 and is headquartered in Greenwich, CT. | Financial Conglomerates | Director/Board Member | |
Opna Immuno-Oncology SA
![]() Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | Biotechnology | Corporate Officer/Principal | |
Opna Bio SA
![]() Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Pharmaceuticals: Generic | Chief Executive Officer |
Statistiche
Distribuzione geografica
Stati Uniti | 12 |
Svizzera | 3 |
Bermuda | 2 |
Canada | 2 |
Settori
Finance | 8 |
Health Technology | 6 |
Consumer Services | 3 |
Process Industries | 2 |
Posizioni
Private Equity Investor | 8 |
Director/Board Member | 5 |
Independent Dir/Board Member | 2 |
Founder | 1 |
Corporate Officer/Principal | 1 |
Contatti più connessi
Insiders | |
---|---|
Reinaldo Diaz | 17 |
- Borsa valori
- Insiders
- Steven Xu Tan
- Connessioni Società